Multi-microarray identifies lower AQP9 expression in adjuvant chemotherapy nonresponders with stage III colorectal cancer

Cancer Letters

Volumn 336, Issue 1, 2013, Pages 106-113

  Dou, Ruoxu ^a   Deng, Yanhong ^a   Huang, Lanlan ^a   Fu, Shijun ^b   Tan, Shuyun ^a   Wang, Lei ^a   Lian, Lei ^a   Fang, Lekun ^a   Fan, Xinjuan ^a   Jin, Gang ^b   Liu, Huanliang ^a   Wang, Jianping ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b Shanghai Biochip Co Ltd   (China)

Author keywords

AQP9; Chemosensitivity; Microarray

Indexed keywords

AQUAPORIN 9; BIOLOGICAL MARKER; CAPECITABINE; FLUOROURACIL; FOLINIC ACID; MICRORNA; OXALIPLATIN;

ADULT; AGED; AQUAPORIN 9 GENE; ARTICLE; CANCER ADJUVANT THERAPY; CANCER STAGING; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; GENE; GENE EXPRESSION REGULATION; GENE IDENTIFICATION; GENETIC ASSOCIATION; HUMAN; MALE; MICROARRAY ANALYSIS; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SATB2 GENE; TREATMENT RESPONSE; WIF1 GENE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; AQUAPORINS; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MATRIX ATTACHMENT REGION BINDING PROTEINS; MICRORNAS; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REPRESSOR PROTEINS; TRANSCRIPTION FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84878973265     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.04.017     Document Type: Article

References (28)

1. Jemal A., Center M.M., DeSantis C., Ward E.M. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol. Biomarkers Prev. 2010, 19:1893-1907.
2. Moertel C.G., Fleming T.R., Macdonald J.S., Haller D.G., Laurie J.A., Goodman P.J., Ungerleider J.S., Emerson W.A., Tormey D.C., Glick J.H., et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N. Engl. J. Med. 1990, 322:352-358.
3. Wolmark N., Rockette H., Mamounas E., Jones J., Wieand S., Wickerham D.L., Bear H.D., Atkins J.N., Dimitrov N.V., Glass A.G., Fisher E.R., Fisher B. Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes' B and C carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project C-04. J. Clin. Oncol. 1999, 17:3553-3559.
4. Andre T., Boni C., Navarro M., Tabernero J., Hickish T., Topham C., Bonetti A., Clingan P., Bridgewater J., Rivera F., de Gramont A. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J. Clin. Oncol. 2009, 27:3109-3116.
5. Engstrom P.F., Arnoletti J.P., Benson A.B., Chen Y.J., Choti M.A., Cooper H.S., Covey A., Dilawari R.A., Early D.S., Enzinger P.C., Fakih M.G., Fleshman J., Fuchs C., Grem J.L., Kiel K., Knol J.A., Leong L.A., Lin E., Mulcahy M.F., Rao S., Ryan D.P., Saltz L., Shibata D., Skibber J.M., Sofocleous C., Thomas J., Venook A.P., Willett C. NCCN clinical practice guidelines in oncology: colon cancer. J. Natl. Compr. Cancer Netw. 2009, 7:778-831.
6. Gray R., Barnwell J., McConkey C., Hills R.K., Williams N.S., Kerr D.J. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet 2007, 370:2020-2029.
7. Sargent D.J., Marsoni S., Monges G., Thibodeau S.N., Labianca R., Hamilton S.R., French A.J., Kabat B., Foster N.R., Torri V., Ribic C., Grothey A., Moore M., Zaniboni A., Seitz J.F., Sinicrope F., Gallinger S. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J. Clin. Oncol. 2010, 28:3219-3226.
8. Russo A., Bazan V., Iacopetta B., Kerr D., Soussi T., Gebbia N. The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment. J. Clin. Oncol. 2005, 23:7518-7528.
9. Allegra C.J., Paik S., Colangelo L.H., Parr A.L., Kirsch I., Kim G., Klein P., Johnston P.G., Wolmark N., Wieand H.S. Prognostic value of thymidylate synthase, Ki-67, and p53 in patients with Dukes' B and C colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project collaborative study. J. Clin. Oncol. 2003, 21:241-250.
10. Kim G.P., Colangelo L.H., Wieand H.S., Paik S., Kirsch I.R., Wolmark N., Allegra C.J. Prognostic and predictive roles of high-degree microsatellite instability in colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project Collaborative Study. J. Clin. Oncol. 2007, 25:767-772.
11. Karlberg M., Ohrling K., Edler D., Hallstrom M., Ullen H., Ragnhammar P. Prognostic and predictive value of thymidylate synthase expression in primary colorectal cancer. Anticancer Res. 2010, 30:645-651.
12. Westra J.L., Hollema H., Schaapveld M., Platteel I., Oien K.A., Keith W.N., Mauritz R., Peters G.J., Buys C.H., Hofstra R.M., Plukker J.T. Predictive value of thymidylate synthase and dihydropyrimidine dehydrogenase protein expression on survival in adjuvantly treated stage III colon cancer patients. Ann. Oncol. 2005, 16:1646-1653.
13. Ong C.W., Kim L.G., Kong H.H., Low L.Y., Iacopetta B., Soong R., Salto-Tellez M. CD133 expression predicts for non-response to chemotherapy in colorectal cancer. Mod. Pathol. 2010, 23:450-457.
14. Gormley J.A., Hegarty S.M., O'Grady A., Stevenson M.R., Burden R.E., Barrett H.L., Scott C.J., Johnston J.A., Wilson R.H., Kay E.W., Johnston P.G., Olwill S.A. The role of Cathepsin S as a marker of prognosis and predictor of chemotherapy benefit in adjuvant CRC: a pilot study. Br. J. Cancer 2011, 105:1487-1494.
15. Thornton M., Aslam M.A., Tweedle E.M., Ang C., Campbell F., Jackson R., Costello E., Rooney P.S., Vlatkovic N., Boyd M.T. The unfolded protein response regulator GRP78 is a novel predictive biomarker in colorectal cancer. Int. J. Cancer 2013.
16. Kawakami K., Matsunoki A., Kaneko M., Saito K., Watanabe G., Minamoto T. Long interspersed nuclear element-1 hypomethylation is a potential biomarker for the prediction of response to oral fluoropyrimidines in microsatellite stable and CpG island methylator phenotype-negative colorectal cancer. Cancer Sci. 2011, 102:166-174.
17. Del Rio M., Molina F., Bascoul-Mollevi C., Copois V., Bibeau F., Chalbos P., Bareil C., Kramar A., Salvetat N., Fraslon C., Conseiller E., Granci V., Leblanc B., Pau B., Martineau P., Ychou M. Gene expression signature in advanced colorectal cancer patients select drugs and response for the use of leucovorin, fluorouracil, and irinotecan. J. Clin. Oncol. 2007, 25:773-780.
18. O'Connell M.J., Lavery I., Yothers G., Paik S., Clark-Langone K.M., Lopatin M., Watson D., Baehner F.L., Shak S., Baker J., Cowens J.W., Wolmark N. Relationship between tumor gene expression and recurrence in four independent studies of patients with stage II/III colon cancer treated with surgery alone or surgery plus adjuvant fluorouracil plus leucovorin. J. Clin. Oncol. 2010, 28:3937-3944.
19. Watanabe T., Kobunai T., Yamamoto Y., Matsuda K., Ishihara S., Nozawa K., Iinuma H., Ikeuchi H. Gene expression of vascular endothelial growth factor A, thymidylate synthase, and tissue inhibitor of metalloproteinase 3 in prediction of response to bevacizumab treatment in colorectal cancer patients. Dis. Colon Rectum 2011, 54:1026-1035.
20. Watanabe T., Komuro Y., Kiyomatsu T., Kanazawa T., Kazama Y., Tanaka J., Tanaka T., Yamamoto Y., Shirane M., Muto T., Nagawa H. Prediction of sensitivity of rectal cancer cells in response to preoperative radiotherapy by DNA microarray analysis of gene expression profiles. Cancer Res. 2006, 66:3370-3374.
21. Nishida N., Nagahara M., Sato T., Mimori K., Sudo T., Tanaka F., Shibata K., Ishii H., Sugihara K., Doki Y., Mori M. Microarray analysis of colorectal cancer stromal tissue reveals upregulation of two oncogenic microRNA clusters. Clin. Cancer Res. 2012.
22. Bustin S.A. Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays. J. Mol. Endocrinol. 2000, 25:169-193.
23. Tsukaguchi H., Shayakul C., Berger U.V., Mackenzie B., Devidas S., Guggino W.B., van Hoek A.N., Hediger M.A. Molecular characterization of a broad selectivity neutral solute channel. J. Biol. Chem. 1998, 273:24737-24743.
24. Liu Z., Shen J., Carbrey J.M., Mukhopadhyay R., Agre P., Rosen B.P. Arsenite transport by mammalian aquaglyceroporins AQP7 and AQP9. Proc. Natl. Acad. Sci. USA 2002, 99:6053-6058.
25. Leung J., Pang A., Yuen W.H., Kwong Y.L., Tse E.W. Relationship of expression of aquaglyceroporin 9 with arsenic uptake and sensitivity in leukemia cells. Blood 2007, 109:740-746.
26. Miao Z.F., Chang E.E., Tsai F.Y., Yeh S.C., Wu C.F., Wu K.Y., Wang C.J., Tsou T.C. Increased aquaglyceroporin 9 expression disrupts arsenic resistance in human lung cancer cells. Toxicol. in Vitro 2009, 23:209-216.
27. Aharon R., Bar-Shavit Z. Involvement of aquaporin 9 in osteoclast differentiation. J. Biol. Chem. 2006, 281:19305-19309.
28. Okada S., Misaka T., Matsumoto I., Watanabe H., Abe K. Aquaporin-9 is expressed in a mucus-secreting goblet cell subset in the small intestine. FEBS Lett. 2003, 540:157-162.